Interestingly, clinical trials targeting mTOR inhibition have been carried out for certain symptoms (subependymal astrocytoma, angiomyolipoma) in tuberous sclerosis (TSC) patients [51,52,53] and is also considered an option for treating neurological symptoms [40,54,55]. This evidence concerns the gene MTOR and tuberous sclerosis.